TY - JOUR
T1 - Impact of physical activity on fatigue and quality of life in people with advanced lung cancer
T2 - A randomized controlled trial
AU - Dhillon, H. M.
AU - Bell, M. L.
AU - van der Ploeg, H. P.
AU - Turner, J. D.
AU - Kabourakis, M.
AU - Spencer, L.
AU - Lewis, C.
AU - Hui, R.
AU - Blinman, P.
AU - Clarke, S. J.
AU - Boyer, M. J.
AU - Vardy, Janette L.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background: Physical activity (PA) improves fatigue and quality of life (QOL) in cancer survivors. Our aim was to assess whether a 2-month PA intervention improves fatigue and QOL for people with advanced lung cancer. Methods: Participants with advanced lung cancer, Eastern Cooperative Oncology Group performance status (PS) ≤ 2, > 6 months life expectancy, and ability to complete six-min walk test, were stratified (disease stage, PS 0-1 versus 2, centre) and randomized (1:1) in an open-label study to usual care (UC) (nutrition and PA education materials) or experimental intervention (EX): UC plus 2-month supervised weekly PA and behaviour change sessions. Assessments occurred at baseline, 2, 4, and 6 months. The primary endpoint was fatigue [Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire] at 2 months. The study was designed to detect a difference in mean FACT-F subscale score of 6. Analysis was intention-to-treat using linear mixed models. Results: We recruited 112 patients: 56 (50.4%) were randomized to EX, 55(49.5%) to UC; 1 ineligible. Male 55%; median age 64 years (34-80); 106 (96%) non-small cell lung cancer; 106 (95.5%) stage IV. At 2, 4 and 6 months, 90, 73 and 62 participants were assessed, respectively, with no difference in attrition between groups. There were no significant differences in fatigue between the groups at 2, 4 or 6 months: mean scores at 2 months EX 37.5, UC 36.4 (difference 1.2, 95% CI - 3.5, 5.8, P=0.62). There were no significant differences in QOL, symptoms, physical or functional status, or survival. Conclusions: Adherence to the intervention was good but the intervention group did not increase their PA enough compared to the control group, and no difference was seen in fatigue or QOL.
AB - Background: Physical activity (PA) improves fatigue and quality of life (QOL) in cancer survivors. Our aim was to assess whether a 2-month PA intervention improves fatigue and QOL for people with advanced lung cancer. Methods: Participants with advanced lung cancer, Eastern Cooperative Oncology Group performance status (PS) ≤ 2, > 6 months life expectancy, and ability to complete six-min walk test, were stratified (disease stage, PS 0-1 versus 2, centre) and randomized (1:1) in an open-label study to usual care (UC) (nutrition and PA education materials) or experimental intervention (EX): UC plus 2-month supervised weekly PA and behaviour change sessions. Assessments occurred at baseline, 2, 4, and 6 months. The primary endpoint was fatigue [Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire] at 2 months. The study was designed to detect a difference in mean FACT-F subscale score of 6. Analysis was intention-to-treat using linear mixed models. Results: We recruited 112 patients: 56 (50.4%) were randomized to EX, 55(49.5%) to UC; 1 ineligible. Male 55%; median age 64 years (34-80); 106 (96%) non-small cell lung cancer; 106 (95.5%) stage IV. At 2, 4 and 6 months, 90, 73 and 62 participants were assessed, respectively, with no difference in attrition between groups. There were no significant differences in fatigue between the groups at 2, 4 or 6 months: mean scores at 2 months EX 37.5, UC 36.4 (difference 1.2, 95% CI - 3.5, 5.8, P=0.62). There were no significant differences in QOL, symptoms, physical or functional status, or survival. Conclusions: Adherence to the intervention was good but the intervention group did not increase their PA enough compared to the control group, and no difference was seen in fatigue or QOL.
KW - Fatigue
KW - Lung cancer
KW - Physical activity
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85029280799&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdx205
DO - 10.1093/annonc/mdx205
M3 - Article
C2 - 28459989
AN - SCOPUS:85029280799
VL - 28
SP - 1889
EP - 1897
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 8
M1 - mdx205
ER -